Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kuti

Showing results (281-290 of 596) with videos related to

Pageof 60
Sort By:
Connecticut Medicine|April 12, 2003
Treatment of Clostridium difficile-associated disease (CDAD)Naomi R Florea, Joseph L Kuti, Charles H Nightingale, et al.
The Central African Journal of Medicine|September 1, 1994
Typhoid fever associated with severe hepatitisJ O Olubodun, J A Kuti, B O Adefuye, et al.
Clinical Therapeutics|October 13, 2004
Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenemHolly M Mattoes, Joseph L Kuti, George L Drusano, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|March 3, 2007
Addressing resistance evolution in Pseudomonas aeruginosa using pharmacodynamic modelling: application to meropenem dosage and combination therapyL Santos Filho, K J Eagye, J L Kuti, et al.
Pediatric Blood & Cancer|May 8, 2009
Optimizing bactericidal exposure for beta-lactams using prolonged and continuous infusions in the pediatric populationJoshua D Courter, Joseph L Kuti, Jennifer E Girotto, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|November 19, 2011
Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administrationSeth T Housman, Pamela R Tessier, David P Nicolau, et al.
Scandinavian Journal of Infectious Diseases|September 30, 2014
Clinical comparison of ertapenem and cefepime for treatment of infections caused by AmpC beta-lactamase-producing EnterobacteriaceaeLisa M Blanchette, Joseph L Kuti, David P Nicolau, et al.
International Journal of Antimicrobial Agents|May 16, 2022
Pharmacokinetics and Time above the MIC Exposure of Cefepime in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation (ECMO)Abigail K Kois, Jason A Gluck, David P Nicolau, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 21, 2025
Non-KPC Attributes of the Newer β-lactam/β-lactamase Inhibitors, Part 2: Burkholderia cepacia complex, Stenotrophomonas maltophilia, and Acinetobacter baumanniiAndrew J Fratoni, Matthew L Gethers, David P Nicolau, et al.
Surgical Infections|July 12, 2024
Effect of Blood Product Resuscitation on Cefazolin Pharmacokinetics in Trauma PatientsAliaa Fouad, Angela Berry, Jonathan Gates, et al.
Pageof 60

Showing results (281-290 of 596) with videos related to

Sort By:
Pageof 60
Connecticut Medicine|April 12, 2003
Treatment of Clostridium difficile-associated disease (CDAD)Naomi R Florea, Joseph L Kuti, Charles H Nightingale, et al.
The Central African Journal of Medicine|September 1, 1994
Typhoid fever associated with severe hepatitisJ O Olubodun, J A Kuti, B O Adefuye, et al.
Clinical Therapeutics|October 13, 2004
Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenemHolly M Mattoes, Joseph L Kuti, George L Drusano, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|March 3, 2007
Addressing resistance evolution in Pseudomonas aeruginosa using pharmacodynamic modelling: application to meropenem dosage and combination therapyL Santos Filho, K J Eagye, J L Kuti, et al.
Pediatric Blood & Cancer|May 8, 2009
Optimizing bactericidal exposure for beta-lactams using prolonged and continuous infusions in the pediatric populationJoshua D Courter, Joseph L Kuti, Jennifer E Girotto, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|November 19, 2011
Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administrationSeth T Housman, Pamela R Tessier, David P Nicolau, et al.
Scandinavian Journal of Infectious Diseases|September 30, 2014
Clinical comparison of ertapenem and cefepime for treatment of infections caused by AmpC beta-lactamase-producing EnterobacteriaceaeLisa M Blanchette, Joseph L Kuti, David P Nicolau, et al.
International Journal of Antimicrobial Agents|May 16, 2022
Pharmacokinetics and Time above the MIC Exposure of Cefepime in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation (ECMO)Abigail K Kois, Jason A Gluck, David P Nicolau, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 21, 2025
Non-KPC Attributes of the Newer β-lactam/β-lactamase Inhibitors, Part 2: Burkholderia cepacia complex, Stenotrophomonas maltophilia, and Acinetobacter baumanniiAndrew J Fratoni, Matthew L Gethers, David P Nicolau, et al.
Surgical Infections|July 12, 2024
Effect of Blood Product Resuscitation on Cefazolin Pharmacokinetics in Trauma PatientsAliaa Fouad, Angela Berry, Jonathan Gates, et al.
Pageof 60